Emitac has also partnered with Belgian IBA, known for the development and manufacture of particle accelerators used in cancer treatment.
IBA is the worldwide leader in proton therapy technology. Over 50% of proton therapy patients have been treated using IBA technology to date.
Strongly committed to remaining at the forefront of innovation, IBA is making a major contribution and developments aiming at making proton therapy more affordable and used for more clinical indications.
IBA has been active in proton therapy for the last 30 years and has built the world’s largest User community, comprising more than 50 proton therapy customers.